title: Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
abstract: The pharmacokinetics and serum bactericidal activities (SBAs) of imipenem and meropenem were investigated in a randomized crossover study. Twelve healthy male volunteers received a constant 30-min infusion of either 1 g of imipenem plus 1 g of cilastatin or 1 g of meropenem. The concentrations of the drugs in serum and urine were determined by bioassay and high-pressure liquid chromatography. Pharmacokinetic parameters were based on an open two-compartment model and a noncompartmental technique. At the end of infusion, the mean concentrations of imipenem and meropenem measured in serum were 61.2 +/- 9.8 and 51.6 +/- 6.5 mg/liter, respectively; urinary recoveries were 48.6% +/- 8.2% and 60.0% +/- 6.5% of the dose in 12 h, respectively; and the areas under the concentration-time curve from time zero to infinity were 96.1 +/- 14.4 and 70.5 +/- 10.3 mg.h/liter, respectively (P < or = 0.02). Imipenem had a mean half-life of 66.7 +/- 10.4 min; that of meropenem was 64.4 +/- 6.9 min. The volumes of distribution at steady state of imipenem and meropenem were 15.3 +/- 3.3 and 18.6 +/- 3.0 liters/70 kg, respectively, and the mean renal clearances per 1.73 m2 were 85.6 +/- 17.6 and 144.6 +/- 26.0 ml/min, respectively. Both antibiotics were well tolerated in this single-dose administration study. The SBAs were measured by the microdilution method of Reller and Stratton (L. B. Reller and C. W. Stratton, J. Infect. Dis. 136:196-204, 1977) against 40 clinically isolated strains. Mean reciprocal bactericidal titers were measured 1 and 6 h after administration. After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis. Both drugs had rather short biological elimination half-lives and a predominantly renal route of elimination. Both carbapenems revealed high SBAs against clinically important pathogens at 1 h; meropenem had a higher SBA against E. cloacae and P. mirabilis, and the SBA of imipenem against S. aureus was greater than the SBA of meropenem.
authors.affiliation: Department for Chest and Infectious Diseases, City-Hospital Zehlendorf, Berlin, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Dreetz
authors.forename: J
authors.initials: J
authors.lastname: Hamacher
authors.forename: J
authors.initials: J
authors.lastname: Eller
authors.forename: K
authors.initials: K
authors.lastname: Borner
authors.forename: P
authors.initials: P
authors.lastname: Koeppe
authors.forename: T
authors.initials: T
authors.lastname: Schaberg
authors.forename: H
authors.initials: H
authors.lastname: Lode
mesh_terms: D000328:Adult; D001770:Blood Bactericidal Activity; D015377:Cilastatin / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D000077728:Cilastatin, Imipenem Drug Combination; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D015378:Imipenem / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D013845:Thienamycins / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics*
chemical_list: D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination; D000077731:Meropenem